English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Phospholipase A2 (PLA2) catalyzes the hydrolysis of the SN-2 acyl ester linkage of phospholipids and producing fatty acids and lysophospholipids. Their activity is one of the rate-limiting steps in the formation of arachidonic acid and in the synthesis of leukotrienes and prostaglandins. These prostaglandins have vital role in carcinogenesis. In the present study structure based drug design approach has applied to the hnps-PLA2 inhibitors. It can be concluded that indole-3-acetamide derivative molecule 13 h was showing better interaction with the active site of hnps-PLA2. The comparative in silico ADME studies proved that 13h molecule could be a potential anticancer drug. Phospholipase is an enzyme that converts phospholipids into fatty acid and other lipophillic-substances. There are four major classes of Phospholipase, termed A, B, C and D. These classes are distinguished by the catalyzing type of reactions. Phospholipase A has two subtypes: Phospholipase A1 which cleaves the SN-1 acyl chain and Phospholipase A2 which cleaves the SN-2 acyl chain.

Design of Human Non-Pancreatic Secretary Phospholipase A2 (hnps-PLA2) Inhibitors: A Structure Based Molecule Design Approach